Clinical trial NCT05727540: The Cohort Study of Uveitis Patients
Official title: The Cohort Study of Uveitis Patients Based on Real-world Data
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Uveitis
Lead sponsor: Zhongshan Ophthalmic Center, Sun Yat-sen University
Sponsor class: OTHER
First posted: 2023-02-14
Enrollment: 600
Sex: ALL
Minimum age (years): 18
Maximum age (years): 90
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: The study population are adult uveitis patients.

Brief summary: This study intends to explore the epidemiology, pathogenesis, clinical manifestations, diagnosis and treatment of uveitis. This is a cohort study. The outcome of the study is the activity of inflammation and visual prognosis. The purpose of this study is to determine the optimal diagnosis and treatment scheme for uveitis patients based on real-world data.


Eligibility criteria: Inclusion Criteria:

* The diagnosis is uveitis; The agreement of enrolling this study;

Exclusion Criteria:

* Uveitis during the first month after any intraocular surgery; \<18 years; pregnant and lactating women; other conditions are unsuitable for participation in this study by the investigator such as mental abnormalities.

Primary outcomes:
measure: The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
timeFrame: 12 months post-treatment
measure: The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
timeFrame: 12 months post-treatment
Secondary outcomes:
measure: Best corrected visual acuity
timeFrame: 1 month post-treatment
measure: Best corrected visual acuity
timeFrame: 3 months post-treatment
measure: Best corrected visual acuity
timeFrame: 6 months post-treatment
measure: Best corrected visual acuity
timeFrame: 12 months post-treatment
measure: Best corrected visual acuity
timeFrame: 24 months post-treatment
measure: Best corrected visual acuity
timeFrame: 36 months post-treatment
measure: The number of intraocular pressure
timeFrame: 1 month post-treatment
measure: The number of intraocular pressure
timeFrame: 3 months post-treatment
measure: The number of intraocular pressure
timeFrame: 6 months post-treatment
measure: The number of Intraocular pressure
timeFrame: 12 months post-treatment
measure: The number of Intraocular pressure
timeFrame: 24 months post-treatment
measure: The number of Intraocular pressure
timeFrame: 36 months post-treatment
measure: Central retinal thickness
timeFrame: 1 month post-treatment
measure: Central retinal thickness
timeFrame: 3 months post-treatment
measure: Central retinal thickness
timeFrame: 6 months post-treatment
measure: Central retinal thickness
timeFrame: 12 months post-treatment
measure: Central retinal thickness
timeFrame: 24 months post-treatment
measure: Central retinal thickness
timeFrame: 36 months post-treatment
measure: The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
timeFrame: 1 month post-treatment
measure: The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
timeFrame: 3 months post-treatment
measure: The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
timeFrame: 6 months post-treatment
measure: The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
timeFrame: 24 months post-treatment
measure: The socre of anterior chamber inflammation based on the Standardization of Uveitis Nomenclature (SUN) scoring system
timeFrame: 36 months post-treatment
measure: The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
timeFrame: 3 months post-treatment
measure: The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
timeFrame: 6 months post-treatment
measure: The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
timeFrame: 24 months post-treatment
measure: The range of inflammatory chorioretinal and/or inflammatory retinal vascular lesions
timeFrame: 36 months post-treatment
Other outcomes:
Locations:
city: Guangzhou
country: China
facility: Zhongshan Ophthalmic Center
state: Guangdong
Study officials:
References: